Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
BioNTech SE Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 144/A Form 144/A - Report of proposed sale of securities: [Amend]
09/29/2023 144 Form 144 - Report of proposed sale of securities:
09/29/2023 144 Form 144 - Report of proposed sale of securities:
08/14/2023 144/A Form 144/A - Report of proposed sale of securities: [Amend]
08/14/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "BioNTech Expands Management Board by Appointing James Ryan as Chief Legal Officer",
"BioNTech Expands Management Board by Appointing James Ryan as Chief Legal Officer"
08/07/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Quarterly Report for the Three and Six Months Ended June 30, 2023",
"Quarterly Report for the Three and Six Months Ended June 30, 2023"
08/07/2023 6-K Quarterly results
Docs: "6-K",
"BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update",
"Second Quarter 2023: Corporate Update and Financial Results"
07/31/2023 6-K Quarterly results
06/29/2023 144 Form 144 - Report of proposed sale of securities:
06/29/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 program in Metastatic NSCLC",
"BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 program in Metastatic NSCLC"
06/28/2023 144 Form 144 - Report of proposed sale of securities:
06/02/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO",
"BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO"
06/02/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Disclosure of share buyback program pursuant to Art. 5(1) lit. a) of Regulation (EU) No. 596/2014 of the European Parliament and the Council of April 16, 2014 and Art. 2(1) of Delegated Regulation (EU) 2016/1052 of the European Commission of March 8, 2016",
"Disclosure of share buyback program pursuant to Art. 5(1) lit. a) of Regulation (EU) No. 596/2014 of the European Parliament and the Council of April 16, 2014 and Art. 2(1) of Delegated Regulation (EU) 2016/1052 of the European Commission of March 8, 2016"
05/26/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with the European Commission",
"Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with the European Commission"
05/25/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Annual General Meeting 2023 Voting Results",
"Changes in the Supervisory Board of BioNTech SE and Voting Results from the Annual General Meeting 2023",
"Annual General Meeting 2023 Presentation",
"Annual General Meeting 2023 Voting Results"
05/08/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Quarterly Report for the Three Months Ended March 31, 2023",
"Quarterly Report for the Three Months Ended March 31, 2023"
05/08/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Quarterly Report for the Three Months Ended March 31, 2023",
"Quarterly Report for the Three Months Ended March 31, 2023"
05/08/2023 6-K Quarterly results
04/13/2023 6-K Quarterly results
04/03/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors",
"BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors"
03/28/2023 6-K Quarterly results
03/27/2023 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
03/27/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"BioNTech Announces Full Year 2022 Financial Results and Corporate Update",
"Fourth Quarter and Full Year 2022: Corporate Update and Financial Results"
03/20/2023 6-K Quarterly results
03/01/2023 6-K Quarterly results
02/24/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Pfizer and BioNTech Submit Supplemental Biologics License Application for U.S. FDA Approval of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine for Ages 12 Years and Older as Primary Series or Booster",
"Pfizer and BioNTech Submit Supplemental Biologics License Application for U.S. FDA Approval of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine for Ages 12 Years and Older as Primary Series or Booster"
02/21/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/14/2023 SC 13G/A ATHOS KG reports a 43.5% stake in BIONTECH SE
02/13/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/13/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
01/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "BioNTech Presents at JP Morgan Healthcare Conference 2023",
"BioNTech Presents at JP Morgan Healthcare Conference 2023"
01/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development",
"BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development"
12/22/2022 6-K Quarterly results
12/09/2022 6-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy